The estimated Net Worth of Thomas W. Burnell is at least $441 Thousand dollars as of 21 May 2021. Dr Burnell owns over 10,855 units of Interpace Biosciences Inc stock worth over $15,957 and over the last 4 years he sold IDXG stock worth over $0. In addition, he makes $425,004 as Pres and CEO & Director at Interpace Biosciences Inc.
Dr has made over 1 trades of the Interpace Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,855 units of IDXG stock worth $94,221 on 21 May 2021.
The largest trade he's ever made was buying 10,855 units of Interpace Biosciences Inc stock on 21 May 2021 worth over $94,221. On average, Dr trades about 5,428 units every 0 days since 2020. As of 21 May 2021 he still owns at least 10,855 units of Interpace Biosciences Inc stock.
You can see the complete history of Dr Burnell stock trades at the bottom of the page.
Dr. Thomas W. Burnell Ph.D. is the Pres, CEO & Director at Interpace Biosciences Inc.
As the Pres and CEO & Director of Interpace Biosciences Inc, the total compensation of Dr D at Interpace Biosciences Inc is $425,004. There are 1 executives at Interpace Biosciences Inc getting paid more, with Jack Stover having the highest compensation of $862,291.
Dr D is 58, he's been the Pres and CEO & Director of Interpace Biosciences Inc since . There are 5 older and 3 younger executives at Interpace Biosciences Inc. The oldest executive at Interpace Biosciences Inc is Stephen Sullivan, 73, who is the Chairman of the Board.
Thomas's mailing address filed with the SEC is C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY, PARSIPPANY, NJ, 07054.
Over the last 9 years, insiders at Interpace Biosciences Inc have traded over $0 worth of Interpace Biosciences Inc stock and bought 94,105 units worth $353,961 . The most active insiders traders include Peter Kamin, Nat Krishnamurti, and Graham G Miao. On average, Interpace Biosciences Inc executives and independent directors trade stock every 99 days with the average trade being worth of $48,561. The most recent stock trade was executed by Thomas W. Burnell on 21 May 2021, trading 10,855 units of IDXG stock currently worth $94,221.
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Interpace Biosciences Inc executives and other stock owners filed with the SEC include: